Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
Yan Tang, Lin Zhang, Yuping Zeng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21

Showing 21 citing articles:

Glucagon‐like peptide agonists: A prospective review
Zamara Mariam, Sarfaraz K. Niazi
Endocrinology Diabetes & Metabolism (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 51
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
Isabella Zaffina, Maria Chiara Pelle, Giuseppe Armentaro, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 19
Tirzepatide-related acute liver injury
Irrum Abdullah, Husam El-Ghousain, Meshaan Alenezi
European Journal of Case Reports in Internal Medicine (2024)
Open Access | Times Cited: 6
2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes
Marcello Casaccia Bertoluci, Wellington S. Silva Júnior, Fernando Valente, et al.
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 13
New insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs
Soraia Pinto, Hélder A. Santos, Bruno Sarmento
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology (2024) Vol. 16, Iss. 2
Open Access | Times Cited: 3
Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses
Shilpa N. Kaore, B Bhavya, Sameer Khasbage, et al.
Cureus (2024)
Open Access | Times Cited: 3
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Richard E. Pratley, Zeb Saeed, Anna Casu
Current Opinion in Gastroenterology (2024) Vol. 40, Iss. 5, pp. 404-412
Closed Access | Times Cited: 3
Dehydrozingerone ameliorates renal structure compromised in diabetic nephropathy
Nivedita Singh, Anuradha Kesharwani, S Sankar, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025), pp. 167894-167894
Closed Access
Polyagonists in Type 2 Diabetes Management
Harsha Dissanayake, N. P. Somasundaram
Current Diabetes Reports (2023) Vol. 24, Iss. 1, pp. 1-12
Closed Access | Times Cited: 5
Expert consensus recommendations on the evaluation and management of hypoglycemia in diabetes: DGENius Group Diabetes India
Amit Dey, Rutul Gokalani, Mayura Kale, et al.
Journal of Diabetology (2024) Vol. 15, Iss. 1, pp. 38-62
Open Access | Times Cited: 1
TIRZEPATIDA, AGONISTA DO RECEPTOR DUPLO DE GIP E GLP-1, NO TRATAMENTO DE DIABETES MELLITUS TIPO 2: EFICÁCIA E SEGURANÇA
Rodolfo Alvarenga Bastos, Ana Gabriela Bonfim Lopes, B OLIVIERI, et al.
RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218 (2024) Vol. 5, Iss. 4, pp. e545133-e545133
Open Access | Times Cited: 1
The effect of incretin-based drugs on the riks of acute pancreatitis: a review
Agata Czaplicka, Beata Kaleta
Journal of Diabetes & Metabolic Disorders (2024) Vol. 23, Iss. 1, pp. 487-495
Closed Access | Times Cited: 1
Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
A B Kamrul-Hasan, Sunetra Mondal, Deep Dutta, et al.
Obesity Science & Practice (2024) Vol. 10, Iss. 6
Open Access | Times Cited: 1
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy
Lina Naseralallah, Bodoor Aboujabal
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 4, pp. 407-418
Open Access | Times Cited: 3
Impact of a dual glucose‐dependent insulinotropic peptide/glucagon‐like peptide‐1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta‐analysis
Yucheng Yang, Liyun He, Peng Liu, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 548-556
Closed Access | Times Cited: 3
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Abhishek Kumar, Rupa Mazumder, Anjna Rani, et al.
Current Diabetes Reviews (2023) Vol. 20, Iss. 4
Closed Access | Times Cited: 2
Safety and Effectiveness of Tirzepatide Use in Obesity Without Type 2 Diabetes Mellitus
Ali M Al Zweihary
Cureus (2024)
Open Access
Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta‐analysis
Jie Gong, Fengwei Gao, Kangyi Jiang, et al.
Journal of Diabetes Investigation (2024)
Open Access
Semaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta‑analysis
Lili Xia, Huihua Li, Shan Huang, et al.
Biomedical Reports (2024) Vol. 22, Iss. 3
Open Access
Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
Zarghuna Khan, Muhammad O Naeem, Saad Khalid Khan, et al.
Cureus (2023)
Open Access | Times Cited: 1
Management of Pediatric Type 2 Diabetes
Sanjukta Basak
Canadian Diabetes & Endocrinology Today (2023)
Open Access
2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes
Marcello Casaccia Bertoluci, Wellington S. Silva Júnior, Fernando Valente, et al.
Revista Portuguesa de Endocrinologia Diabetes e Metabolismo (2023), Iss. 1
Open Access
Page 1

Scroll to top